Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules which are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which includes host and foreign substances.

Get Sample PDF Here @ https://www.theinsightpartners.com/sample/TIPRE00026641/

According to our latest study on “Monoclonal Antibodies Market Size and Forecast to 2028 – COVID-19 Impact and Global Analysis – by Source, Production Method, Indication, Application, End-User,” the market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

Based on indication, the monoclonal antibody market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. The cancer segment held the largest share of the market in 2021 and is projected to register the highest CAGR during the forecast period. On the other hand, the autoimmune diseases segment is estimated to register the second-highest CAGR in the market during the forecast period. Cancer metastasis causes a majority of mortalities and morbidities among cancer patients. A traditional cancer therapy focuses on the removal or destruction of tumor cells through surgery, radiation, and rather non-selective types of chemotherapy. Therefore, there is a high demand for antitumor monoclonal antibodies (mABs). For example, the Food and Drug Administration (FDA)has approved several specially engineered humanized or chimeric mABs; these include Alemtuzumab, Bevacizumab, and Cetuximab. Apart from the direct use of mAbs for treating various cancer types, mABs are also used for delivering radioisotopes selectively to cancer cells. For example, mAB-tagged radioisotopes are used for treating patients suffering from non-Hodgkin's lymphoma and are often used in combination with Rituximab.

The monoclonal antibodies market is majorly comprised of top players involving Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company.

Read Complete Report Here @ https://www.theinsightpartners.com/reports/monoclonal-antibodies-market

The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.

About Us:                                                                                                                          

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com